March 2025
Placement Agent
€13 million
PIPE
MaaT Pharma
Placement Agent
Van Lanschot Kempen acted as Placement Agent in the Capital Increase by MaaT Pharma
Transaction highlights
- MaaT Pharma raised €13 million of fresh equity, with the support of existing shareholders Biocodex and Bpifrance amongst others, against a challenging equity market backdrop for life sciences companies
- The net proceeds will support the company’s progress towards key value milestones, including marketing authorization submission for EMA approval of MaaT013 in acute Graft-versus-Host Disease (aGvHD), its US expansion strategy, and extend the cash runway into October 2025
- The company is actively discussing additional dilutive and non-dilutive financing options for 2025, which, together with a potential strategic partnership would further finance and accelerate its development activities
- We are proud to have again assisted MaaT Pharma, a long-standing client of our firm, following our role as Joint Global Coordinator in the company’s Initial Public Offering in 2021
Company description
MaaT Pharma is a late-stage clinical company focused on developing full ecosystem microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Lead asset, MaaT013, read out positive topline results in its pivotal Phase 3 ARES study for acute Graft-versus-Host Disease, showing a significant gastrointestinal overall response rate of 62%, confirming MaaT013 as a third-line treatment for acute Graft-versus-Host Disease with gastrointestinal involvement. The company anticipates submitting a Marketing Authorization Application with the EMA in June 2025 and discussions are ongoing with the FDA to expedite MaaT013’s clinical development plan in the United States.
Background Van Lanschot Kempen Life Sciences & Healthcare
In the last twelve months, Van Lanschot Kempen has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:
- Sole Financial Adviser in Pharming’s SEK 725 million public takeover of Abliva
- Sole Financial Adviser in GENFIT’s royalty financing up to €185 million
- Sole Financial Adviser in IO Biotech’s c. €58 million loan facility from the European Investment Bank
- Financial Adviser in the USD 479 million US Public Offering by NewAmsterdam Pharma
- Sole Financial Adviser to SNIPR Biome in securing a €20 million venture debt facility from the European Investment Bank
- Lead Manager in the USD 1 billion Capital Increase by Zealand Pharma
- Lead Manager in the USD 460 million Capital Increase by Merus
- Sole Financial Adviser in Pharming’s refinancing of its convertible bonds
- Financial Adviser in the SEK 107 million Rights Issue by Alligator Bioscience